img

Global Neurologic Disorder Treatment Drug Market Research Report 2024


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Neurologic Disorder Treatment Drug Market Research Report 2024

According to Mr Accuracy reports’s new survey, global Neurologic Disorder Treatment Drug market is projected to reach US$ million in 2034, increasing from US$ million in 2024, with the CAGR of % during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Neurologic Disorder Treatment Drug market research.
Key companies engaged in the Neurologic Disorder Treatment Drug industry include AbbVie, Acadia Pharmaceuticals, Acorda Therapeutics Biotechnology, Bayer, Biogen, CSK, Eisai, F. Hoffmann La Roche and H Lundbeck, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2024.
When refers to consumption region, % value of Neurologic Disorder Treatment Drug were sold to North America, Europe and Asia Pacific in 2024. Moreover, China, plays a key role in the whole Neurologic Disorder Treatment Drug market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Neurologic Disorder Treatment Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


AbbVie
Acadia Pharmaceuticals
Acorda Therapeutics Biotechnology
Bayer
Biogen
CSK
Eisai
F. Hoffmann La Roche
H Lundbeck
Johnson and Johnson
Merck
Novartis
Otsuka Pharmaceutical
Pfizer
Sanofi
Takeda Pharmaceutical
Teva Pharmaceutical Industries
UCB
USWM
Segment by Type
Anticholinergic
Antiepileptic
Antipsychotic
Hypnotic and Sedative
Analgesics
Antihypertensive
Anticoagulants
Others

Segment by Application


Epilepsy
Alzheimer’s Disease
Parkinson's Disease
Multiple Sclerosis
Cerebrovascular Disease
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Neurologic Disorder Treatment Drug report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neurologic Disorder Treatment Drug Market Size Growth Rate by Type: 2018 VS 2024 VS 2034
1.2.2 Anticholinergic
1.2.3 Antiepileptic
1.2.4 Antipsychotic
1.2.5 Hypnotic and Sedative
1.2.6 Analgesics
1.2.7 Antihypertensive
1.2.8 Anticoagulants
1.2.9 Others
1.3 Market by Application
1.3.1 Global Neurologic Disorder Treatment Drug Market Growth by Application: 2018 VS 2024 VS 2034
1.3.2 Epilepsy
1.3.3 Alzheimer’s Disease
1.3.4 Parkinson's Disease
1.3.5 Multiple Sclerosis
1.3.6 Cerebrovascular Disease
1.3.7 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neurologic Disorder Treatment Drug Market Perspective (2018-2034)
2.2 Neurologic Disorder Treatment Drug Growth Trends by Region
2.2.1 Global Neurologic Disorder Treatment Drug Market Size by Region: 2018 VS 2024 VS 2034
2.2.2 Neurologic Disorder Treatment Drug Historic Market Size by Region (2018-2023)
2.2.3 Neurologic Disorder Treatment Drug Forecasted Market Size by Region (2024-2034)
2.3 Neurologic Disorder Treatment Drug Market Dynamics
2.3.1 Neurologic Disorder Treatment Drug Industry Trends
2.3.2 Neurologic Disorder Treatment Drug Market Drivers
2.3.3 Neurologic Disorder Treatment Drug Market Challenges
2.3.4 Neurologic Disorder Treatment Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neurologic Disorder Treatment Drug Players by Revenue
3.1.1 Global Top Neurologic Disorder Treatment Drug Players by Revenue (2018-2023)
3.1.2 Global Neurologic Disorder Treatment Drug Revenue Market Share by Players (2018-2023)
3.2 Global Neurologic Disorder Treatment Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Neurologic Disorder Treatment Drug Revenue
3.4 Global Neurologic Disorder Treatment Drug Market Concentration Ratio
3.4.1 Global Neurologic Disorder Treatment Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neurologic Disorder Treatment Drug Revenue in 2024
3.5 Neurologic Disorder Treatment Drug Key Players Head office and Area Served
3.6 Key Players Neurologic Disorder Treatment Drug Product Solution and Service
3.7 Date of Enter into Neurologic Disorder Treatment Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neurologic Disorder Treatment Drug Breakdown Data by Type
4.1 Global Neurologic Disorder Treatment Drug Historic Market Size by Type (2018-2023)
4.2 Global Neurologic Disorder Treatment Drug Forecasted Market Size by Type (2024-2034)
5 Neurologic Disorder Treatment Drug Breakdown Data by Application
5.1 Global Neurologic Disorder Treatment Drug Historic Market Size by Application (2018-2023)
5.2 Global Neurologic Disorder Treatment Drug Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America Neurologic Disorder Treatment Drug Market Size (2018-2034)
6.2 North America Neurologic Disorder Treatment Drug Market Growth Rate by Country: 2018 VS 2024 VS 2034
6.3 North America Neurologic Disorder Treatment Drug Market Size by Country (2018-2023)
6.4 North America Neurologic Disorder Treatment Drug Market Size by Country (2024-2034)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Neurologic Disorder Treatment Drug Market Size (2018-2034)
7.2 Europe Neurologic Disorder Treatment Drug Market Growth Rate by Country: 2018 VS 2024 VS 2034
7.3 Europe Neurologic Disorder Treatment Drug Market Size by Country (2018-2023)
7.4 Europe Neurologic Disorder Treatment Drug Market Size by Country (2024-2034)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neurologic Disorder Treatment Drug Market Size (2018-2034)
8.2 Asia-Pacific Neurologic Disorder Treatment Drug Market Growth Rate by Region: 2018 VS 2024 VS 2034
8.3 Asia-Pacific Neurologic Disorder Treatment Drug Market Size by Region (2018-2023)
8.4 Asia-Pacific Neurologic Disorder Treatment Drug Market Size by Region (2024-2034)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Neurologic Disorder Treatment Drug Market Size (2018-2034)
9.2 Latin America Neurologic Disorder Treatment Drug Market Growth Rate by Country: 2018 VS 2024 VS 2034
9.3 Latin America Neurologic Disorder Treatment Drug Market Size by Country (2018-2023)
9.4 Latin America Neurologic Disorder Treatment Drug Market Size by Country (2024-2034)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neurologic Disorder Treatment Drug Market Size (2018-2034)
10.2 Middle East & Africa Neurologic Disorder Treatment Drug Market Growth Rate by Country: 2018 VS 2024 VS 2034
10.3 Middle East & Africa Neurologic Disorder Treatment Drug Market Size by Country (2018-2023)
10.4 Middle East & Africa Neurologic Disorder Treatment Drug Market Size by Country (2024-2034)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AbbVie
11.1.1 AbbVie Company Detail
11.1.2 AbbVie Business Overview
11.1.3 AbbVie Neurologic Disorder Treatment Drug Introduction
11.1.4 AbbVie Revenue in Neurologic Disorder Treatment Drug Business (2018-2023)
11.1.5 AbbVie Recent Development
11.2 Acadia Pharmaceuticals
11.2.1 Acadia Pharmaceuticals Company Detail
11.2.2 Acadia Pharmaceuticals Business Overview
11.2.3 Acadia Pharmaceuticals Neurologic Disorder Treatment Drug Introduction
11.2.4 Acadia Pharmaceuticals Revenue in Neurologic Disorder Treatment Drug Business (2018-2023)
11.2.5 Acadia Pharmaceuticals Recent Development
11.3 Acorda Therapeutics Biotechnology
11.3.1 Acorda Therapeutics Biotechnology Company Detail
11.3.2 Acorda Therapeutics Biotechnology Business Overview
11.3.3 Acorda Therapeutics Biotechnology Neurologic Disorder Treatment Drug Introduction
11.3.4 Acorda Therapeutics Biotechnology Revenue in Neurologic Disorder Treatment Drug Business (2018-2023)
11.3.5 Acorda Therapeutics Biotechnology Recent Development
11.4 Bayer
11.4.1 Bayer Company Detail
11.4.2 Bayer Business Overview
11.4.3 Bayer Neurologic Disorder Treatment Drug Introduction
11.4.4 Bayer Revenue in Neurologic Disorder Treatment Drug Business (2018-2023)
11.4.5 Bayer Recent Development
11.5 Biogen
11.5.1 Biogen Company Detail
11.5.2 Biogen Business Overview
11.5.3 Biogen Neurologic Disorder Treatment Drug Introduction
11.5.4 Biogen Revenue in Neurologic Disorder Treatment Drug Business (2018-2023)
11.5.5 Biogen Recent Development
11.6 CSK
11.6.1 CSK Company Detail
11.6.2 CSK Business Overview
11.6.3 CSK Neurologic Disorder Treatment Drug Introduction
11.6.4 CSK Revenue in Neurologic Disorder Treatment Drug Business (2018-2023)
11.6.5 CSK Recent Development
11.7 Eisai
11.7.1 Eisai Company Detail
11.7.2 Eisai Business Overview
11.7.3 Eisai Neurologic Disorder Treatment Drug Introduction
11.7.4 Eisai Revenue in Neurologic Disorder Treatment Drug Business (2018-2023)
11.7.5 Eisai Recent Development
11.8 F. Hoffmann La Roche
11.8.1 F. Hoffmann La Roche Company Detail
11.8.2 F. Hoffmann La Roche Business Overview
11.8.3 F. Hoffmann La Roche Neurologic Disorder Treatment Drug Introduction
11.8.4 F. Hoffmann La Roche Revenue in Neurologic Disorder Treatment Drug Business (2018-2023)
11.8.5 F. Hoffmann La Roche Recent Development
11.9 H Lundbeck
11.9.1 H Lundbeck Company Detail
11.9.2 H Lundbeck Business Overview
11.9.3 H Lundbeck Neurologic Disorder Treatment Drug Introduction
11.9.4 H Lundbeck Revenue in Neurologic Disorder Treatment Drug Business (2018-2023)
11.9.5 H Lundbeck Recent Development
11.10 Johnson and Johnson
11.10.1 Johnson and Johnson Company Detail
11.10.2 Johnson and Johnson Business Overview
11.10.3 Johnson and Johnson Neurologic Disorder Treatment Drug Introduction
11.10.4 Johnson and Johnson Revenue in Neurologic Disorder Treatment Drug Business (2018-2023)
11.10.5 Johnson and Johnson Recent Development
11.11 Merck
11.11.1 Merck Company Detail
11.11.2 Merck Business Overview
11.11.3 Merck Neurologic Disorder Treatment Drug Introduction
11.11.4 Merck Revenue in Neurologic Disorder Treatment Drug Business (2018-2023)
11.11.5 Merck Recent Development
11.12 Novartis
11.12.1 Novartis Company Detail
11.12.2 Novartis Business Overview
11.12.3 Novartis Neurologic Disorder Treatment Drug Introduction
11.12.4 Novartis Revenue in Neurologic Disorder Treatment Drug Business (2018-2023)
11.12.5 Novartis Recent Development
11.13 Otsuka Pharmaceutical
11.13.1 Otsuka Pharmaceutical Company Detail
11.13.2 Otsuka Pharmaceutical Business Overview
11.13.3 Otsuka Pharmaceutical Neurologic Disorder Treatment Drug Introduction
11.13.4 Otsuka Pharmaceutical Revenue in Neurologic Disorder Treatment Drug Business (2018-2023)
11.13.5 Otsuka Pharmaceutical Recent Development
11.14 Pfizer
11.14.1 Pfizer Company Detail
11.14.2 Pfizer Business Overview
11.14.3 Pfizer Neurologic Disorder Treatment Drug Introduction
11.14.4 Pfizer Revenue in Neurologic Disorder Treatment Drug Business (2018-2023)
11.14.5 Pfizer Recent Development
11.15 Sanofi
11.15.1 Sanofi Company Detail
11.15.2 Sanofi Business Overview
11.15.3 Sanofi Neurologic Disorder Treatment Drug Introduction
11.15.4 Sanofi Revenue in Neurologic Disorder Treatment Drug Business (2018-2023)
11.15.5 Sanofi Recent Development
11.16 Takeda Pharmaceutical
11.16.1 Takeda Pharmaceutical Company Detail
11.16.2 Takeda Pharmaceutical Business Overview
11.16.3 Takeda Pharmaceutical Neurologic Disorder Treatment Drug Introduction
11.16.4 Takeda Pharmaceutical Revenue in Neurologic Disorder Treatment Drug Business (2018-2023)
11.16.5 Takeda Pharmaceutical Recent Development
11.17 Teva Pharmaceutical Industries
11.17.1 Teva Pharmaceutical Industries Company Detail
11.17.2 Teva Pharmaceutical Industries Business Overview
11.17.3 Teva Pharmaceutical Industries Neurologic Disorder Treatment Drug Introduction
11.17.4 Teva Pharmaceutical Industries Revenue in Neurologic Disorder Treatment Drug Business (2018-2023)
11.17.5 Teva Pharmaceutical Industries Recent Development
11.18 UCB
11.18.1 UCB Company Detail
11.18.2 UCB Business Overview
11.18.3 UCB Neurologic Disorder Treatment Drug Introduction
11.18.4 UCB Revenue in Neurologic Disorder Treatment Drug Business (2018-2023)
11.18.5 UCB Recent Development
11.19 USWM
11.19.1 USWM Company Detail
11.19.2 USWM Business Overview
11.19.3 USWM Neurologic Disorder Treatment Drug Introduction
11.19.4 USWM Revenue in Neurologic Disorder Treatment Drug Business (2018-2023)
11.19.5 USWM Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Neurologic Disorder Treatment Drug Market Size Growth Rate by Type (US$ Million): 2018 VS 2024 VS 2034
Table 2. Key Players of Anticholinergic
Table 3. Key Players of Antiepileptic
Table 4. Key Players of Antipsychotic
Table 5. Key Players of Hypnotic and Sedative
Table 6. Key Players of Analgesics
Table 7. Key Players of Antihypertensive
Table 8. Key Players of Anticoagulants
Table 9. Key Players of Others
Table 10. Global Neurologic Disorder Treatment Drug Market Size Growth by Application (US$ Million): 2018 VS 2024 VS 2034
Table 11. Global Neurologic Disorder Treatment Drug Market Size by Region (US$ Million): 2018 VS 2024 VS 2034
Table 12. Global Neurologic Disorder Treatment Drug Market Size by Region (2018-2023) & (US$ Million)
Table 13. Global Neurologic Disorder Treatment Drug Market Share by Region (2018-2023)
Table 14. Global Neurologic Disorder Treatment Drug Forecasted Market Size by Region (2024-2034) & (US$ Million)
Table 15. Global Neurologic Disorder Treatment Drug Market Share by Region (2024-2034)
Table 16. Neurologic Disorder Treatment Drug Market Trends
Table 17. Neurologic Disorder Treatment Drug Market Drivers
Table 18. Neurologic Disorder Treatment Drug Market Challenges
Table 19. Neurologic Disorder Treatment Drug Market Restraints
Table 20. Global Neurologic Disorder Treatment Drug Revenue by Players (2018-2023) & (US$ Million)
Table 21. Global Neurologic Disorder Treatment Drug Market Share by Players (2018-2023)
Table 22. Global Top Neurologic Disorder Treatment Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurologic Disorder Treatment Drug as of 2024)
Table 23. Ranking of Global Top Neurologic Disorder Treatment Drug Companies by Revenue (US$ Million) in 2024
Table 24. Global 5 Largest Players Market Share by Neurologic Disorder Treatment Drug Revenue (CR5 and HHI) & (2018-2023)
Table 25. Key Players Headquarters and Area Served
Table 26. Key Players Neurologic Disorder Treatment Drug Product Solution and Service
Table 27. Date of Enter into Neurologic Disorder Treatment Drug Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Neurologic Disorder Treatment Drug Market Size by Type (2018-2023) & (US$ Million)
Table 30. Global Neurologic Disorder Treatment Drug Revenue Market Share by Type (2018-2023)
Table 31. Global Neurologic Disorder Treatment Drug Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 32. Global Neurologic Disorder Treatment Drug Revenue Market Share by Type (2024-2034)
Table 33. Global Neurologic Disorder Treatment Drug Market Size by Application (2018-2023) & (US$ Million)
Table 34. Global Neurologic Disorder Treatment Drug Revenue Market Share by Application (2018-2023)
Table 35. Global Neurologic Disorder Treatment Drug Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 36. Global Neurologic Disorder Treatment Drug Revenue Market Share by Application (2024-2034)
Table 37. North America Neurologic Disorder Treatment Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2024 VS 2034
Table 38. North America Neurologic Disorder Treatment Drug Market Size by Country (2018-2023) & (US$ Million)
Table 39. North America Neurologic Disorder Treatment Drug Market Size by Country (2024-2034) & (US$ Million)
Table 40. Europe Neurologic Disorder Treatment Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2024 VS 2034
Table 41. Europe Neurologic Disorder Treatment Drug Market Size by Country (2018-2023) & (US$ Million)
Table 42. Europe Neurologic Disorder Treatment Drug Market Size by Country (2024-2034) & (US$ Million)
Table 43. Asia-Pacific Neurologic Disorder Treatment Drug Market Size Growth Rate by Region (US$ Million): 2018 VS 2024 VS 2034
Table 44. Asia-Pacific Neurologic Disorder Treatment Drug Market Size by Region (2018-2023) & (US$ Million)
Table 45. Asia-Pacific Neurologic Disorder Treatment Drug Market Size by Region (2024-2034) & (US$ Million)
Table 46. Latin America Neurologic Disorder Treatment Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2024 VS 2034
Table 47. Latin America Neurologic Disorder Treatment Drug Market Size by Country (2018-2023) & (US$ Million)
Table 48. Latin America Neurologic Disorder Treatment Drug Market Size by Country (2024-2034) & (US$ Million)
Table 49. Middle East & Africa Neurologic Disorder Treatment Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2024 VS 2034
Table 50. Middle East & Africa Neurologic Disorder Treatment Drug Market Size by Country (2018-2023) & (US$ Million)
Table 51. Middle East & Africa Neurologic Disorder Treatment Drug Market Size by Country (2024-2034) & (US$ Million)
Table 52. AbbVie Company Detail
Table 53. AbbVie Business Overview
Table 54. AbbVie Neurologic Disorder Treatment Drug Product
Table 55. AbbVie Revenue in Neurologic Disorder Treatment Drug Business (2018-2023) & (US$ Million)
Table 56. AbbVie Recent Development
Table 57. Acadia Pharmaceuticals Company Detail
Table 58. Acadia Pharmaceuticals Business Overview
Table 59. Acadia Pharmaceuticals Neurologic Disorder Treatment Drug Product
Table 60. Acadia Pharmaceuticals Revenue in Neurologic Disorder Treatment Drug Business (2018-2023) & (US$ Million)
Table 61. Acadia Pharmaceuticals Recent Development
Table 62. Acorda Therapeutics Biotechnology Company Detail
Table 63. Acorda Therapeutics Biotechnology Business Overview
Table 64. Acorda Therapeutics Biotechnology Neurologic Disorder Treatment Drug Product
Table 65. Acorda Therapeutics Biotechnology Revenue in Neurologic Disorder Treatment Drug Business (2018-2023) & (US$ Million)
Table 66. Acorda Therapeutics Biotechnology Recent Development
Table 67. Bayer Company Detail
Table 68. Bayer Business Overview
Table 69. Bayer Neurologic Disorder Treatment Drug Product
Table 70. Bayer Revenue in Neurologic Disorder Treatment Drug Business (2018-2023) & (US$ Million)
Table 71. Bayer Recent Development
Table 72. Biogen Company Detail
Table 73. Biogen Business Overview
Table 74. Biogen Neurologic Disorder Treatment Drug Product
Table 75. Biogen Revenue in Neurologic Disorder Treatment Drug Business (2018-2023) & (US$ Million)
Table 76. Biogen Recent Development
Table 77. CSK Company Detail
Table 78. CSK Business Overview
Table 79. CSK Neurologic Disorder Treatment Drug Product
Table 80. CSK Revenue in Neurologic Disorder Treatment Drug Business (2018-2023) & (US$ Million)
Table 81. CSK Recent Development
Table 82. Eisai Company Detail
Table 83. Eisai Business Overview
Table 84. Eisai Neurologic Disorder Treatment Drug Product
Table 85. Eisai Revenue in Neurologic Disorder Treatment Drug Business (2018-2023) & (US$ Million)
Table 86. Eisai Recent Development
Table 87. F. Hoffmann La Roche Company Detail
Table 88. F. Hoffmann La Roche Business Overview
Table 89. F. Hoffmann La Roche Neurologic Disorder Treatment Drug Product
Table 90. F. Hoffmann La Roche Revenue in Neurologic Disorder Treatment Drug Business (2018-2023) & (US$ Million)
Table 91. F. Hoffmann La Roche Recent Development
Table 92. H Lundbeck Company Detail
Table 93. H Lundbeck Business Overview
Table 94. H Lundbeck Neurologic Disorder Treatment Drug Product
Table 95. H Lundbeck Revenue in Neurologic Disorder Treatment Drug Business (2018-2023) & (US$ Million)
Table 96. H Lundbeck Recent Development
Table 97. Johnson and Johnson Company Detail
Table 98. Johnson and Johnson Business Overview
Table 99. Johnson and Johnson Neurologic Disorder Treatment Drug Product
Table 100. Johnson and Johnson Revenue in Neurologic Disorder Treatment Drug Business (2018-2023) & (US$ Million)
Table 101. Johnson and Johnson Recent Development
Table 102. Merck Company Detail
Table 103. Merck Business Overview
Table 104. Merck Neurologic Disorder Treatment Drug Product
Table 105. Merck Revenue in Neurologic Disorder Treatment Drug Business (2018-2023) & (US$ Million)
Table 106. Merck Recent Development
Table 107. Novartis Company Detail
Table 108. Novartis Business Overview
Table 109. Novartis Neurologic Disorder Treatment Drug Product
Table 110. Novartis Revenue in Neurologic Disorder Treatment Drug Business (2018-2023) & (US$ Million)
Table 111. Novartis Recent Development
Table 112. Otsuka Pharmaceutical Company Detail
Table 113. Otsuka Pharmaceutical Business Overview
Table 114. Otsuka Pharmaceutical Neurologic Disorder Treatment Drug Product
Table 115. Otsuka Pharmaceutical Revenue in Neurologic Disorder Treatment Drug Business (2018-2023) & (US$ Million)
Table 116. Otsuka Pharmaceutical Recent Development
Table 117. Pfizer Company Detail
Table 118. Pfizer Business Overview
Table 119. Pfizer Neurologic Disorder Treatment Drug Product
Table 120. Pfizer Revenue in Neurologic Disorder Treatment Drug Business (2018-2023) & (US$ Million)
Table 121. Pfizer Recent Development
Table 122. Sanofi Company Detail
Table 123. Sanofi Business Overview
Table 124. Sanofi Neurologic Disorder Treatment Drug Product
Table 125. Sanofi Revenue in Neurologic Disorder Treatment Drug Business (2018-2023) & (US$ Million)
Table 126. Sanofi Recent Development
Table 127. Takeda Pharmaceutical Company Detail
Table 128. Takeda Pharmaceutical Business Overview
Table 129. Takeda Pharmaceutical Neurologic Disorder Treatment Drug Product
Table 130. Takeda Pharmaceutical Revenue in Neurologic Disorder Treatment Drug Business (2018-2023) & (US$ Million)
Table 131. Takeda Pharmaceutical Recent Development
Table 132. Teva Pharmaceutical Industries Company Detail
Table 133. Teva Pharmaceutical Industries Business Overview
Table 134. Teva Pharmaceutical Industries Neurologic Disorder Treatment Drug Product
Table 135. Teva Pharmaceutical Industries Revenue in Neurologic Disorder Treatment Drug Business (2018-2023) & (US$ Million)
Table 136. Teva Pharmaceutical Industries Recent Development
Table 137. UCB Company Detail
Table 138. UCB Business Overview
Table 139. UCB Neurologic Disorder Treatment Drug Product
Table 140. UCB Revenue in Neurologic Disorder Treatment Drug Business (2018-2023) & (US$ Million)
Table 141. UCB Recent Development
Table 142. USWM Company Detail
Table 143. USWM Business Overview
Table 144. USWM Neurologic Disorder Treatment Drug Product
Table 145. USWM Revenue in Neurologic Disorder Treatment Drug Business (2018-2023) & (US$ Million)
Table 146. USWM Recent Development
Table 147. Research Programs/Design for This Report
Table 148. Key Data Information from Secondary Sources
Table 149. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neurologic Disorder Treatment Drug Market Size Comparison by Type (2023-2034) & (US$ Million)
Figure 2. Global Neurologic Disorder Treatment Drug Market Share by Type: 2024 VS 2034
Figure 3. Anticholinergic Features
Figure 4. Antiepileptic Features
Figure 5. Antipsychotic Features
Figure 6. Hypnotic and Sedative Features
Figure 7. Analgesics Features
Figure 8. Antihypertensive Features
Figure 9. Anticoagulants Features
Figure 10. Others Features
Figure 11. Global Neurologic Disorder Treatment Drug Market Size Comparison by Application (2023-2034) & (US$ Million)
Figure 12. Global Neurologic Disorder Treatment Drug Market Share by Application: 2024 VS 2034
Figure 13. Epilepsy Case Studies
Figure 14. Alzheimer’s Disease Case Studies
Figure 15. Parkinson's Disease Case Studies
Figure 16. Multiple Sclerosis Case Studies
Figure 17. Cerebrovascular Disease Case Studies
Figure 18. Others Case Studies
Figure 19. Neurologic Disorder Treatment Drug Report Years Considered
Figure 20. Global Neurologic Disorder Treatment Drug Market Size (US$ Million), Year-over-Year: 2018-2034
Figure 21. Global Neurologic Disorder Treatment Drug Market Size, (US$ Million), 2018 VS 2024 VS 2034
Figure 22. Global Neurologic Disorder Treatment Drug Market Share by Region: 2024 VS 2034
Figure 23. Global Neurologic Disorder Treatment Drug Market Share by Players in 2024
Figure 24. Global Top Neurologic Disorder Treatment Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurologic Disorder Treatment Drug as of 2024)
Figure 25. The Top 10 and 5 Players Market Share by Neurologic Disorder Treatment Drug Revenue in 2024
Figure 26. North America Neurologic Disorder Treatment Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 27. North America Neurologic Disorder Treatment Drug Market Share by Country (2018-2034)
Figure 28. United States Neurologic Disorder Treatment Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 29. Canada Neurologic Disorder Treatment Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 30. Europe Neurologic Disorder Treatment Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 31. Europe Neurologic Disorder Treatment Drug Market Share by Country (2018-2034)
Figure 32. Germany Neurologic Disorder Treatment Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 33. France Neurologic Disorder Treatment Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 34. U.K. Neurologic Disorder Treatment Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 35. Italy Neurologic Disorder Treatment Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 36. Russia Neurologic Disorder Treatment Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 37. Nordic Countries Neurologic Disorder Treatment Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 38. Asia-Pacific Neurologic Disorder Treatment Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 39. Asia-Pacific Neurologic Disorder Treatment Drug Market Share by Region (2018-2034)
Figure 40. China Neurologic Disorder Treatment Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 41. Japan Neurologic Disorder Treatment Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 42. South Korea Neurologic Disorder Treatment Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 43. Southeast Asia Neurologic Disorder Treatment Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 44. India Neurologic Disorder Treatment Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 45. Australia Neurologic Disorder Treatment Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 46. Latin America Neurologic Disorder Treatment Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 47. Latin America Neurologic Disorder Treatment Drug Market Share by Country (2018-2034)
Figure 48. Mexico Neurologic Disorder Treatment Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 49. Brazil Neurologic Disorder Treatment Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 50. Middle East & Africa Neurologic Disorder Treatment Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 51. Middle East & Africa Neurologic Disorder Treatment Drug Market Share by Country (2018-2034)
Figure 52. Turkey Neurologic Disorder Treatment Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 53. Saudi Arabia Neurologic Disorder Treatment Drug Market Size YoY Growth (2018-2034) & (US$ Million)
Figure 54. AbbVie Revenue Growth Rate in Neurologic Disorder Treatment Drug Business (2018-2023)
Figure 55. Acadia Pharmaceuticals Revenue Growth Rate in Neurologic Disorder Treatment Drug Business (2018-2023)
Figure 56. Acorda Therapeutics Biotechnology Revenue Growth Rate in Neurologic Disorder Treatment Drug Business (2018-2023)
Figure 57. Bayer Revenue Growth Rate in Neurologic Disorder Treatment Drug Business (2018-2023)
Figure 58. Biogen Revenue Growth Rate in Neurologic Disorder Treatment Drug Business (2018-2023)
Figure 59. CSK Revenue Growth Rate in Neurologic Disorder Treatment Drug Business (2018-2023)
Figure 60. Eisai Revenue Growth Rate in Neurologic Disorder Treatment Drug Business (2018-2023)
Figure 61. F. Hoffmann La Roche Revenue Growth Rate in Neurologic Disorder Treatment Drug Business (2018-2023)
Figure 62. H Lundbeck Revenue Growth Rate in Neurologic Disorder Treatment Drug Business (2018-2023)
Figure 63. Johnson and Johnson Revenue Growth Rate in Neurologic Disorder Treatment Drug Business (2018-2023)
Figure 64. Merck Revenue Growth Rate in Neurologic Disorder Treatment Drug Business (2018-2023)
Figure 65. Novartis Revenue Growth Rate in Neurologic Disorder Treatment Drug Business (2018-2023)
Figure 66. Otsuka Pharmaceutical Revenue Growth Rate in Neurologic Disorder Treatment Drug Business (2018-2023)
Figure 67. Pfizer Revenue Growth Rate in Neurologic Disorder Treatment Drug Business (2018-2023)
Figure 68. Sanofi Revenue Growth Rate in Neurologic Disorder Treatment Drug Business (2018-2023)
Figure 69. Takeda Pharmaceutical Revenue Growth Rate in Neurologic Disorder Treatment Drug Business (2018-2023)
Figure 70. Teva Pharmaceutical Industries Revenue Growth Rate in Neurologic Disorder Treatment Drug Business (2018-2023)
Figure 71. UCB Revenue Growth Rate in Neurologic Disorder Treatment Drug Business (2018-2023)
Figure 72. USWM Revenue Growth Rate in Neurologic Disorder Treatment Drug Business (2018-2023)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed